SEC Form 4 · accession 0001209191-16-123070
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James L Tyree
Director
Period of report
May 21, 2016
Accepted (ET)
May 24, 2016 · 7:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 21, 2016 | M | 11,795 | $0.00 | A | 26,119 | D | |
| Common StockF3 | May 23, 2016 | S | 5,544 | $4.3898 | D | 20,575 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F5 | — | May 21, 2016 | M | 11,795 | D | — | — | Common Stock | 11,795 | 0 | D |
Explanation of responses
- F1Shares were acquired upon vesting of restricted stock units awarded on May 21, 2015.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover estimated taxes due upon vesting of restricted stock units.
- F3Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $4.25 to $4.59 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- F4Each restricted stock unit represents a contingent right to receive one share of CCXI common stock.
- F5100% of the restricted stock units vested on May 21, 2016. Vested shares will be delivered to the Reporting Person within thirty (30) days following the vesting date.